Interventional treatment of hepatocellular carcinoma

Article Oncology

Hepatic Arterial Infusion of Oxaliplatin Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial

Qi-Jiong Li et al.

Summary: This study compared the overall survival of patients with unresectable large hepatocellular carcinoma treated with FOLFOX-HAIC or TACE as first-line therapy. The results showed that FOLFOX-HAIC significantly improved overall survival compared to TACE, with higher treatment response rate and longer progression-free survival.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1)

Ning Lyu et al.

Summary: In this phase III trial, hepatic arterial infusion chemotherapy (HAIC-FO) showed better survival outcomes than sorafenib in advanced hepatocellular carcinoma (HCC) patients. HAIC-FO responders had significantly improved prognosis compared to non-responders, and a gene prediction model was developed to predict response to HAIC-FO treatment.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Oncology

Interventional Radiology for Local Immunotherapy in Oncology

Lambros Tselikas et al.

Summary: Technical considerations play a crucial role in the success and development of HIT-IT, impacting safety, efficacy, and patient outcomes. Image-guided tumor access can enhance treatment efficacy by increasing intratumoral drug concentration while minimizing systemic exposure. Direct access to the tumor allows for sequential sampling to better understand drug dynamics and efficacy.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Changing trends in hepatocellular carcinoma management: Results from a nationwide database in the last decade

Christophe Cassinotto et al.

Summary: Therapeutic strategies for hepatocellular carcinoma (HCC) have expanded in recent years, with an increase in the number of procedures performed annually. Trans-arterial chemoembolization was the most commonly performed technical procedure, while percutaneous thermal ablation emerged as the main curative treatment for HCC patients.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Review Gastroenterology & Hepatology

Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Locoregional therapies, including local ablation and transarterial chemoembolization, play a crucial role in the management of hepatocellular carcinoma. Recent studies have shown potential benefits of combining these local therapies with systemic treatments, such as molecular therapies, to enhance therapeutic effects.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology